Alcaftadine
Lastacaft (alcaftadine) is a small molecule pharmaceutical. Alcaftadine was first approved as Lastacaft on 2010-07-28. It is used to treat allergic conjunctivitis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Lastacaft
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alcaftadine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LASTACAFT | AbbVie | N-022134 OTC | 2010-07-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lastacaft | New Drug Application | 2022-08-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
605 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 10 | 28 | 3 | 2 | 5 | 44 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 11 | 17 | 3 | 3 | 2 | 32 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 8 | 4 | 8 | 12 | 30 |
| Neoplasms | D009369 | C80 | 19 | 6 | — | 1 | 2 | 24 | |
| Ascites | D001201 | HP_0001541 | R18 | 2 | 2 | 4 | 5 | 5 | 17 |
| Septic shock | D012772 | A48.3 | 2 | 5 | 6 | 2 | 3 | 16 | |
| Sepsis | D018805 | A41.9 | 1 | 3 | 7 | 2 | 3 | 14 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 3 | — | 1 | 6 | 10 |
| Hepatorenal syndrome | D006530 | K76.7 | 1 | 6 | 3 | 1 | 3 | 10 | |
| Squamous cell carcinoma of head and neck | D000077195 | 4 | 5 | 1 | 1 | — | 10 |
Show 51 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 5 | 16 | 4 | — | 1 | 25 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 5 | 11 | 2 | — | 3 | 18 |
| Triple negative breast neoplasms | D064726 | 4 | 7 | 1 | — | 1 | 11 | ||
| Uterine cervical neoplasms | D002583 | 1 | 7 | 1 | — | 1 | 10 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 1 | 1 | — | 4 | 8 |
| Neoadjuvant therapy | D020360 | — | 4 | 2 | — | — | 5 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | 3 | — | 1 | 5 |
| Covid-19 | D000086382 | U07.1 | — | 3 | 1 | — | 1 | 5 | |
| Nasopharyngeal neoplasms | D009303 | 1 | 2 | 1 | — | — | 4 | ||
| Prostatic neoplasms | D011471 | C61 | 2 | 1 | 1 | — | — | 4 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal squamous cell carcinoma | D000077277 | 2 | 13 | — | — | — | 14 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 5 | 7 | — | — | — | 12 |
| Fibrosis | D005355 | — | 3 | — | — | 5 | 8 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | 6 | — | — | 1 | 7 | |
| Adenocarcinoma | D000230 | 2 | 3 | — | — | 2 | 6 | ||
| Chronic renal insufficiency | D051436 | N18 | — | 3 | — | — | 3 | 6 | |
| Head and neck neoplasms | D006258 | 3 | 2 | — | — | — | 5 | ||
| Melanoma | D008545 | 1 | 3 | — | — | — | 4 | ||
| Esophageal neoplasms | D004938 | C15 | 2 | 4 | — | — | — | 4 | |
| Immunotherapy | D007167 | — | 4 | — | — | — | 4 |
Show 68 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 2 | 3 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 2 | — | — | — | — | 2 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | 1 | 2 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | — | — | — | 1 | 2 |
| Peritoneal neoplasms | D010534 | 1 | — | — | — | — | 1 | ||
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | — | — | — | — | 1 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
| Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | 1 | — | — | — | — | 1 |
| Verrucous carcinoma | D018289 | 1 | — | — | — | — | 1 | ||
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | — | 3 | 3 | ||
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Aortic valve disease | D000082862 | — | — | — | — | 2 | 2 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 2 | 2 | |
| Colonic neoplasms | D003110 | C18 | — | — | — | — | 2 | 2 | |
| Liver failure | D017093 | HP_0001399 | K72.9 | — | — | — | — | 2 | 2 |
| Hemolysis | D006461 | — | — | — | — | 2 | 2 | ||
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Cardiogenic shock | D012770 | R57.0 | — | — | — | — | 1 | 1 |
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALCAFTADINE |
| INN | alcaftadine |
| Description | Alcaftadine is an imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is an aldehyde, a member of piperidines, an imidazobenzazepine and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 147084-10-4 |
| RxCUI | 1000082 |
| ChEMBL ID | CHEMBL1201747 |
| ChEBI ID | 71023 |
| PubChem CID | 19371515 |
| DrugBank | DB06766 |
| UNII ID | 7Z8O94ECSX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,725 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more